Format

Send to

Choose Destination
Arch Pathol Lab Med. 2013 Aug;137(8):1047-53. doi: 10.5858/arpa.2012-0193-OA.

Mucin expression in gastric cancer: reappraisal of its clinicopathologic and prognostic significance.

Author information

1
Department of Surgery, Pusan National University Hospital, Busan, Korea.

Erratum in

  • Arch Pathol Lab Med. 2013 Dec;137(12):1706.

Abstract

CONTEXT:

The clinical validity of mucin expression in gastric cancer is debated. Whereas several reports demonstrate a correlation between mucin expression and prognosis, others deny such an association.

OBJECTIVES:

This survival analysis study aims to elucidate the prognostic significance of mucin expression in gastric cancer.

DESIGN:

A retrospective survival analysis was done with 412 cases of gastric cancer characterized on the basis of MUC immunohistochemistry using MUC2, MUC5AC, MUC6, and CD10 antibodies; the cases were divided into those with a gastric, an intestinal, or a null mucin phenotype based on the predominant mucin.

RESULTS:

There was no association between mucin expression and survival when considering overall gastric cancers or the advanced gastric cancer subtype. However, early gastric cancers with a gastric mucin phenotype showed longer survival than those with an intestinal mucin phenotype (P = .01) or a null phenotype (P = .01). In particular, MUC5AC-positive early gastric cancers resulted in longer survival than did those that did not express MUC5AC (P = .009). The loss of MUC5AC expression was identified as an independent, poor prognostic factor in early gastric cancers using the Cox regression proportional hazard model (hazard ratio, 3.50; P = .045).

CONCLUSIONS:

MUC5AC expression is significantly associated with patient survival and can be used to predict outcomes in the gastric cancers, especially in the early gastric cancers.

PMID:
23899060
DOI:
10.5858/arpa.2012-0193-OA
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Allen Press, Inc.
Loading ...
Support Center